An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters

NCT01112345 · clinicaltrials.gov ↗
COMPLETED
Status
133
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Merck KGaA, Darmstadt, Germany

Collaborators